MedTrace Logo

SMART Protocol vs Antagonist Protocol in IVF

NCT05677828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 426

Last updated 2023-03-29

No results posted yet for this study

Summary

This retrospective study aims to assess the effect of adding letrozole in patients who have previously undergone an IVF cycle with either an antagonist or short protocol, with patients who have undergone a second cycle of IVF with an antagonist or short protocol without the addition of letrozole.

Conditions

  • Diminished Ovarian Reserve

Sponsors & Collaborators

  • Clinique Ovo

    lead INDUSTRY

Principal Investigators

  • Robert Hemmings, MD · Clinique Ovo

Eligibility

Min Age
20 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2022-12-12
Completion
2023-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05677828 on ClinicalTrials.gov